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Hepatitis C virus (HCV) establishes a persistent infection that in many cases leads to cirrhosis
and hepatocellular carcinoma. The non-structural 5A protein (NS5A) has been implicated in this
process as it contains a C-terminal polyproline motif (termed P2) that binds to Src homology 3
(SH3) domains to regulate cellular signalling and trafficking pathways. We have shown
previously that NS5A impaired epidermal growth factor (EGF) receptor (EGFR) endocytosis,
thereby inhibiting EGF-stimulated EGFR degradation by a mechanism that remained unclear.
As EGFR has been implicated in HCV cell entry and trafficking of the receptor involves several
SH3-domain containing proteins, we investigated in more detail the mechanisms by which
NS5A perturbs EGFR trafficking. We demonstrated that the P2 motif was required for the
NS5A-mediated disruption to EGFR trafficking. We further demonstrated that the P2 motif was
required for an interaction between NS5A and CMS, a homologue of CIN85 that has previously
been implicated in EGFR endocytosis. We provided evidence that CMS was involved in the
NS5A-mediated perturbation of EGFR trafficking. We also showed that NS5A effected a loss of
EGFR ubiquitination in a P2-motif-dependent fashion. These data provide clues to the
mechanism by which NS5A regulates the trafficking of a key cellular receptor and demonstrate
for the first time the ability of NS5A to regulate host cell ubiquitination pathways.
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INTRODUCTION
Hepatitis C virus (HCV) is an enveloped virus with a
positive-sense, ssRNA genome belonging to the genus
Hepacivirus within the family Flaviviridae. The 9.6 kb HCV
genome encodes a single large polyprotein of 3000 aa
which is processed co- and post-translationally by viral
and host cellular proteases into 10 functional proteins.
These include three structural proteins (core, E1 and E2)
and seven non-structural proteins (p7, NS2, NS3, NS4A,
NS4B, NS5A and NS5B) (Scheel & Rice, 2013).
One of these non-structural proteins, NS5A, is an RNA-
binding phosphoprotein essential for both viral replication
and viral particle assembly (Ross-Thriepland & Harris,
2015). It is composed of an N-terminal amphipathic
helix that mediates membrane association (Elazar et al.,
2003) followed by three domains separated by two low-
complexity sequences (LCSs) (Tellinghuisen et al., 2004).
The structure of domain I has been determined (Lambert
et al., 2014; Love et al., 2009; Tellinghuisen et al., 2005)
and this domain binds to RNA (Foster et al., 2010;
Huang et al., 2005). Domain II is required for RNA repli-
cation (Ross-Thriepland et al., 2013) and domain III is
involved in virion assembly (Appel et al., 2008; Hughes
et al., 2009a). The LCS between domains II and III is pro-
line-rich (Fig. 1a) and, of note, contains a highly conserved
PxxPxR sequence (Macdonald et al., 2004, 2005b; Tan
et al., 1999). This sequence matches the consensus for a
class II SH3-domain-binding motif (Mayer, 2001) and is
referred to herein as the P2 motif. Several cellular SH3-
domain-containing binding partners for the P2 motif
have been identified (Macdonald et al., 2004; Nanda
et al., 2006), but their roles in the HCV life cycle remain
undefined.
NS5A is known to coordinate key interactions among viral
and host proteins to aid virus pathogenesis (Ross-Thriepland
&Harris, 2015).Our previouswork demonstrated thatNS5A
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Fig. 1. NS5A increases EGFR levels in a polyproline motif-dependent manner. (a) Schematic representation of the domain
structure of NS5A. Numbers represent amino acid positions from JFH-1 (genotype 2a). The P2 polyproline motif in LCSII
between residues 338 and 352 is indicated. Residues in bold show the conserved prolines and arginine in P2, and underlin-
ing shows those residues substituted by alanine in the PA2 mutant. AH, amphipathic helix. (b) Samples of 16105 control
Huh7 cells, or cells harbouring either WT or PA2 SGR-neo-JFH-1, were seeded in six-well plates. Cells were trypsinized and
(a)
S
G
R
 W
T
S
G
R
 P
A
2
H
uh
7
(d)
MergeNS5A EGFR 
10 ×106
9 ×105
8 ×105
7 ×105
6 ×105
5 ×105
4 ×105
3 ×105
2 ×105
1 ×105
0
Time (h)
24 7248
C
el
l n
um
be
r
Huh7
SGR WT
SGR PA2
JFH-1 NS5A
P2 polyproline motif:  WT
PA2
(b) (c) –EGF
Huh7
WB
GAPDH
WB
NS5A
WB
EGFR
SGR
Huh7 WT PA2 WT PA2
SGR JFH-1
+EGF
1 2 3
4 5 6 7 8
WB
GAPDH
WB
NS5A
WB
EGFR
LCSI LCSII
WT PA2
AH 32 Domain I Domain II Domain III213 240 352 467338Zn2+
Z. Igloi and others
2134 Journal of General Virology 96
Downloaded from www.microbiologyresearch.org by
IP:  129.11.22.210
On: Thu, 03 Dec 2015 10:20:00
could disrupt the trafficking and degradation of the
epidermal growth factor receptor (EGFR) during HCV infec-
tion (Macdonald et al., 2005a; Mankouri et al., 2008).
Wedemonstrated that this effectwas not due todirect binding
of NS5A to the EGFR, but the mechanism remained unclear.
The EGFR has emerged as a key HCV entry factor (Diao et al.,
2012; Lupberger et al., 2011) and EGFR signalling has been
shown to influence HCV replication (Lupberger et al.,
2013). Therefore, to fully define the role of NS5A in these
processes, we set out to investigate the mechanism by which
HCV NS5A disrupts EGFR trafficking and the cellular co-
factors by which NS5A mediates this effect.
We show here that the P2 motif of NS5A is required for the
disruption of EGFR trafficking, implicating interactions
between NS5A and cellular SH3-domain-containing pro-
teins in this process. We identify the ubiquitously
expressed adaptor molecule, Cas ligand with multiple
SH3 domains (CMS) [also known as CD2-associated
protein (CD2AP)], as an SH3-domain-containing NS5A-
interacting protein and a candidate for a role in NS5A-
mediated perturbation of EGFR trafficking. We further
demonstrate that NS5A disrupts EGFR ubiquitination in
a P2-dependent manner. These data provide a mechanistic
insight detailing how NS5A controls EGFR trafficking and
provides the first evidence that NS5A can regulate host cell
ubiquitination.
RESULTS
NS5A inhibits EGFR degradation in a P2-motif-
dependent fashion
EGFR is known to undergo clathrin-mediated endocytosis
preceding early to late endosomal trafficking and subsequent
degradation (Zheng et al., 2014). We have previously shown
that NS5A partially localized to early endosomes and,
although it had no effect on EGF internalization, colocalized
with the EGFR and altered its distribution (Mankouri et al.,
2008). This redistribution correlated with a decrease in the
amount of active EGF–EGFR ligand–receptor complexes
present in the late endosomal signalling compartment and
also resulted in a concomitant increase in the total levels
of EGFR. The mechanism(s) by which NS5A mediated this
effect were not elucidated; however, we reasoned that the
P2 motif might play a role in this effect by mediating inter-
actions with host cell factor(s). As we have previously shown
that this motif was not required for virus replication
(Hughes et al., 2009b), we were therefore able to evaluate
the cellular functions of the P2 motif in Huh7 cells either
stably harbouring subgenomic replicons (SGRs) or infected
with JFH-1 virus in which the motif had been disrupted
by alanine substitution (PA2).
When the ligand-bound EGFR reaches the late endosomal
compartment it activates a number of signalling cascades
leading to stimulation of cell growth and division. One
consequence of NS5A perturbation of EGFR trafficking
might therefore be a reduction in the rate of cell growth.
This is indeed what we observed (Fig. 1b); whereas the
doubling time of nai¨ve Huh7 cells was *24 h, those har-
bouring the WT SGR exhibited a doubling time of
*48 h. Consistent with a role for the P2 motif in perturb-
ing EGFR signalling, the growth rate of cells harbouring a
PA2 mutant SGR was partially restored and they exhibited
an intermediate phenotype.
To assess this phenotype biochemically we therefore exam-
ined the consequences of the PA2 mutation on EGFR
turnover. A comparison of control Huh7 cells and those
expressing NS5A, both in the context of a SGR or infected
with HCV, revealed a decrease in the rate of EGFR degra-
dation and enhanced EGFR levels both prior to and post-
EGF stimulation (Fig. 1c, compare lanes 1/2 and 4/5).
Interestingly the PA2 mutant exhibited a reduction in
EGFR levels compared with WT, suggesting that this
mutant impaired the ability of NS5A to block EGFR degra-
dation (Fig. 1c, compare lanes 2/3, 5/6 and 7/8). Of note,
the PA2 mutant exhibited an intermediate phenotype as
levels of EGFR were not as low as in nai¨ve Huh7 cells
(Fig. 1c, compare lanes 1–3 and 4–6), consistent with the
intermediate growth phenotype in Fig. 1(b). The same
phenomenon was also observed with immunofluores-
cence, staining for endogenous EGFR and NS5A (Fig.
1d). The intermediate phenotype seen with the PA2
mutant suggested that whilst the P2 motif was necessary
for perturbation of EGFR endocytosis by NS5A, it was
not sufficient and other interactions contributed to the
process.
Following EGF stimulation, a high proportion of interna-
lized EGFR colocalized with the late endosomal marker
CD63. We previously showed that, in NS5A-expressing
cells, there was a significant decrease in the intracellular
accumulation of EGFR in CD63+ late endosomes
(Mankouri et al., 2008). Using Texas red (TR)-conjugated
EGF to track the endocytosis of EGFR we confirmed that,
counted at 24, 48 and 72 h post-seeding. (c) Control Huh7 cells (lanes 1, 4), cells harbouring either WT (lanes 2, 5) or PA2
(lanes 3, 6) SGR-neo-JFH-1, or cells electroporated with 10 mg JFH-1 virus RNA (WT or PA2 mutant, lanes 7, 8) were
serum starved overnight and either stimulated with 50 ng EGF ml21 for 30 min or left unstimulated. Lysates were Western
blotted (WB) for endogenous EGFR, NS5A and glyceraldehyde 3-phosphate dehydrogenase (GAPDH). (d) Control Huh7
cells, or cells harbouring either WT or PA2 SGR-neo-JFH-1, were serum starved overnight and stimulated with 50 ng EGF
ml21 for 30 min prior to fixation and permeabilization. Cells were stained for NS5A (green) and endogenous EGFR
(magenta), and analysed by confocal microscopy. Bar, 10 mm.
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in control cells, *85% of EGF colocalized with CD63,
whereas this was reduced to 15% in cells expressing
NS5A (Fig. 2a, b). In cells expressing PA2 mutant NS5A,
EGF translocation to the late endosomal compartment
was partially restored; 46% of the EGF colocalized with
CD63, again consistent with the intermediate phenotype
of this mutant shown in Fig. 1. This further demonstrated
a critical role for the NS5A P2 motif in the disruption of
EGFR trafficking and subsequent degradation, but again
implicated a role for other interactions mediated by
NS5A in a non-P2-motif-dependent fashion.
NS5A binds to CMS, a known mediator of EGFR
endocytosis
EGFR trafficking is dependent on its coordinated inter-
action with several SH3-domain-containing proteins
(Zheng et al., 2014). Many SH3 domains have been
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Fig. 2. PA2 mutation partially restores EGFR translocation to late endosomal compartments. (a) Mock-transfected Huh7
cells, or cells transfected with plasmids expressing either WT or PA2 NS5A (Macdonald et al., 2004), were serum-starved
overnight prior to stimulation with 100 ng EGF–TR ml21 for 20 min. Cells were then fixed, permeabilized and probed for
CD63 using a mouse anti-CD63 antibody followed by an Alexa Fluor 488-conjugated anti-mouse secondary (green) and
NS5A using anti-sheep NS5A followed by Alexa Fluor 633 (blue). Cells were fixed and analysed by confocal microscopy.
Bar, 10 mm. (b) Percentage of EGF–TR translocation to late endosomes was quantified by staining for CD63 and analysis
using Bitplane software as described previously (Mankouri et al., 2008).
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shown to bind to NS5A in a P2-motif-dependent fashion
(Macdonald et al., 2004; Nanda et al., 2006; Tan et al.,
1999) and we therefore exploited a phage display library
expressing all 296 SH3 domains in the human genome
(Ka¨rkka¨inen et al., 2006) to identify NS5A interactors
that might explain the NS5A-mediated effects on EGFR
trafficking. We generated WT and PA2 mutant JFH-1-
derived SGRs in which a truncated form of the Propioni-
bacterium shermanii transcarboxylase domain (DPSTCD)
was inserted into domain III of NS5A to express an
NS5A-DPSTCD fusion protein. This tag acted as a biotin
acceptor allowing streptavidin-based purification of the
NS5A-DPSTCD fusion protein (McCormick et al., 2006).
WT and PA2 NS5A-DPSTCD were purified from SGR-
harbouring cell lysates using streptavidin-magnetic beads
and used to screen the SH3 domain phage display library
as described (Neuvonen et al., 2011). The SH3 domains
of a number of previously reported NS5A-binding part-
ners, including the Src kinases Hck, Lyn, Src (Macdonald
et al., 2004; Shelton & Harris, 2008) and Amphiphysin II
(Amph2, also known as Bin1) (Nanda et al., 2006), were
identified. In addition, several novel interacting partners
were discovered, including mixed-lineage kinase (Mlk3),
further characterization of which is described elsewhere
(Amako et al., 2013), and the CIN85 homologue, CMS
(Dikic, 2002) (Fig. 3a). This was of interest as both CIN85
and CMS have been implicated in EGFR endocytosis
(Kirsch et al., 2001). To validate the result of the phage
screen, the interaction of NS5A with CMS was confirmed
by co-immunoprecipitation. WT or PA2 SGR-harbouring
cells were transfected with a plasmid expressing CMS with
a C-terminal PinPoint (PP) tag (a commercially available
variant of PSTCD), and lysates were precipitated with strep-
tavidin-magnetic beads and analysed by Western blotting.
This analysis showed that CMS bound to WT NS5A, but
this interaction was reduced by introduction of the PA2
mutation (Fig. 3b). Furthermore, NS5A expressed from
the DPSTCD-containing SGR also interacted with endogen-
ous CMS in a P2-motif-dependent fashion (Fig. 3c).
CMS contains three SH3 domains (Fig. 3a); the phage
display screen identified that domains I and II mediated
its interaction with WT NS5A. To confirm this, the indi-
vidual SH3 domains of CMS were expressed as gluta-
thione S-transferase (GST) fusions, purified and used in
GST-pulldown experiments with lysates from either WT
or PA2 SGR-harbouring cells. Fig. 3(d) shows that,
although WT but not PA2 NS5A bound to all three
SH3 domains, a clear preference for domains I and II
existed. Taken together, these data verified CMS as a
novel interacting partner of HCV NS5A.
CMS can rescue EGFR degradation during HCV
infection
We next sought to assess the involvement of the NS5A–
CMS interaction in EGFR trafficking. CMS was expressed
as a fusion with the PP tag (CMS–PP) in WT and PA2
SGR-harbouring cells, and EGFR levels were analysed by
Western blotting. In control samples (non-transfected
and empty vector), a blockade of EGFR degradation by
NS5A post-EGF stimulation (Fig. 4a, lanes 2 and 5) was
observed. The PA2 SGR exhibited an intermediate pheno-
type (Fig. 4a, lanes 3 and 6), consistent with the data shown
in Fig. 1(c). Interestingly, following exogenous expression
of CMS–PP, EGF-mediated EGFR degradation was
restored in WT NS5A-expressing cells, where a clear loss
of EGFR levels was observed (Fig. 4a, lane 8). This was
not the case when two other SH3 domain-containing pro-
teins, Amph2-Myc and Grb2–YFP (yellow fluorescent pro-
tein), also known to participate in EGFR endocytosis and
trafficking, and to interact with NS5A, were exogenously
expressed (Fig. 4b, lanes 5 and 8). These data demonstrated
that CMS could specifically restore EGFR degradation in
NS5A-expressing cells, implicating the NS5A–CMS inter-
action as a key event governing this process. Intriguingly,
ablation of CMS expression by small interfering RNA had
no effect on EGFR degradation in either control Huh7
cells or SGR-harbouring cells (data not shown). This
could be explained by the fact that CMS shares overlapping
binding specificities and biological functions with CIN85 –
an adaptor that also plays an essential role in EGFR lyso-
some trafficking and degradation. Thus, CIN85 might be
able to functionally compensate for the lack of CMS.
NS5A mediates a loss of EGFR ubiquitination
following EGF stimulation
CIN85, together with the ubiquitin ligase casitas B-lineage
lymphoma (c-Cbl), is known to be vital for the ubiquitina-
tion of EGFR (Eden et al., 2012; Haglund et al., 2002;
Kirsch et al., 2001; Soubeyran et al., 2002; Szymkiewicz
et al., 2002). Although partial ubiquitination of the EGFR
occurs at the cell surface (Stang et al., 2000), it is not
required for internalization (Huang et al., 2007). EGFR
ubiquitination is instead postulated to be required for the
progression from early endosomes to late endosomes/
multivesicular bodies (Grøvdal et al., 2004; Huang et al.,
2013). Given this body of evidence, we reasoned that
EGFR ubiquitination might be the pathway altered by NS5A.
To test this, control or SGR-harbouring cells were trans-
fected with plasmids expressing haemagglutinin (HA)-
tagged ubiquitin (Ubi–HA) and an EGFR–GFP fusion.
After serum starvation and EGF stimulation, EGFR–GFP
was immunoprecipitated using the GFP-Trap system and
immunoprecipitates were Western blotted for the presence
of Ubi–HA. When compared with control Huh7 cells, WT
SGR-harbouring cells exhibited a significant loss of recep-
tor ubiquitination from 0 to 60 min post-EGF stimulation
(Fig. 5a, compare lanes 2–5 and 6–9). Furthermore, the
PA2 mutation restored receptor ubiquitination post-EGF
stimulation to levels similar to those of control Huh7
cells (Fig. 5a, lanes 10–13). No signal was observed in
mock-transfected Huh7 cells (Fig. 5a, lane 1). These data
suggested that in response to ligand stimulation, NS5A
HCV NS5A polyproline motif and EGFR
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mediated a rapid loss of EGFR ubiquitination. Intriguingly,
unlike the intermediate phenotype of the PA2 mutant
observed previously (Figs. 1 and 2), in this case the
mutation resulted in a complete restoration of EGFR ubi-
quitination. This was consistent with the proposal that
NS5A interacted with the EGFR endocytic pathway at mul-
tiple stages and that these may involve different inter-
actions of the viral protein with cellular factors, not all of
which are mediated via P2 binding to SH3 domains.
It has previously been reported that EGFR ubiquitination
and subsequent degradation is disrupted by perturbing
complex formation between CIN85 and c-Cbl (Soubeyran
et al., 2002; Szymkiewicz et al., 2002). c-Cbl can bind to
the EGFR either directly or indirectly via Grb2 in an SH3
domain-directed fashion (Grøvdal et al., 2004).
We further investigated the interaction of c-Cbl with
EGFR, Grb2 and CMS in either control Huh7 cells or
those harbouring either WT or PA2 SGR to define the
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Fig. 3. CMS specifically binds to the P2 motif in NS5A. (a) Schematic of the domain structure of CMS. CMS is composed of
three N-terminal SH3 domains (SH3-I, -II and -III), followed by a proline-rich (PR) region, an unstructured region of ,160
residues (UN) and a C-terminal coiled-coil (CC) domain. Numbers represent amino acid positions. (b) Control Huh7 cells, or
WT or PA2 SGR-harbouring cells, were transfected with a plasmid expressing CMS–PP. At 36 h post-transfection the cells
were serum-starved overnight prior to stimulation with 50 ng EGF ml21 for 30 min. Lysates were precipitated using streptavi-
din beads and the eluted fractions analysed by Western blotting (WB) with an antibody to NS5A or streptavidin–HRP
(Strep–HRP; to detect CMS–PP). (c) Control Huh7 cells, or cells harbouring WT or PA2 SGR-neo-JFH-1 in which NS5A
was tagged with the DPSTCD-tag (McCormick et al., 2006), were serum-starved overnight prior to stimulation with 50 ng
EGF ml21 for 30 min. Lysates were precipitated using streptavidin beads. The eluted fractions were analysed by Western
blotting (WB) with antibody to endogenous CMS or streptavidin–HRP (Strep–HRP; to detect NS5A-DPSTCD). (d) Purified
GST or GST-tagged CMS SH3 domains (SH3 I, II and III for the three SH3 domains in CMS, respectively) were bound to
glutathione-agarose beads and incubated overnight with lysates from cells harbouring WT or PA2 SGR-neo-JFH-1.The
eluted fractions were separated on SDS-PAGE and Western blotted (WB) for NS5A; 15% of the amount used for the pull-
down experiment was loaded as input. Densitometry analysis of bound NS5A is displayed as a percentage of bound
NS5A: GST-SH3 ratio underneath the Western blot.
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molecular events underpinning the effects of NS5A. First,
the ability of c-Cbl to interact with EGFR either directly
or via Grb2 was tested. Cells were transiently transfected
with plasmids expressing EGFR–GFP and HA-tagged
c-Cbl (Cbl–HA), and the lysates were immunoprecipitated
using the GFP-Trap system and probed for the presence of
Cbl–HA (Fig. 5b). Western blot analysis revealed that c-Cbl
was able to interact with EGFR and this interaction was
unaffected by the presence of the SGR (WT or PA2)
(Fig. 5b, lanes 4–6). In a similar experiment, cells were
transfected with plasmids expressing YFP-tagged Grb2
and Cbl–HA. Western blot analysis of the GFP-Trap preci-
pitated fractions showed that c-Cbl was able to interact
with Grb2 and this interaction was again unaffected by
the SGR (Fig. 5c, lanes 4–6). As described previously
(Macdonald et al., 2005a), WT NS5A, but not the PA2
mutant, precipitated with Grb2 (Fig. 5c, lanes 5 and 6).
The presence of both NS5A and c-Cbl in the immunopre-
cipitated fractions suggested that NS5A and c-Cbl did not
compete for a single binding site on Grb2 and may co-
interact with each of the two Grb2 SH3 domains.
As NS5A did not appear to disrupt the interaction between
c-Cbl, Grb2 and EGFR, we next assessed whether the effect
on EGFR ubiquitination could be explained by the effects of
NS5A on the interactions between the adaptor CMS and
either EGFR or c-Cbl. Control or SGR-harbouring Huh7
cells were transfected with plasmids expressing c-Cbl–HA
and CMS–PP. CMS–PP was precipitated using streptavi-
din-magnetic beads and Western blotted for the presence
of Cbl–HA and NS5A. As shown in Fig. 5(d), c-Cbl was
able to bind to CMS in both the absence and presence of
NS5A (Fig. 5d, lanes 4–6), suggesting that the c-Cbl–CMS
interaction remained unaffected. Consistent with the
GST-pulldown data, CMS–PP did not interact with the
PA2 mutant NS5A (Fig. 5d, lane 6). Taken together, these
data indicated that the SH3-binding domain of NS5A
modulated the ubiquitination status of EGFR, but this
was not due to the inhibition of c-Cbl–EGFR binding.
DISCUSSION
It is known that HCV perturbs the cellular environment to
favour its own replication; however, much remains
unknown about how HCV proteins elicit such cellular
changes. In this regard, NS5A has previously been shown
to colocalize with the EGFR and alter its distribution
during HCV infection (Mankouri et al., 2008). This redis-
tribution correlates with a decrease in the levels of EGF–
EGFR ligand–receptor complexes in the late endosomal/
lysosomal compartment and results in a concomitant
increase in the total levels of EGFR in HCV-infected cells.
Here, we investigated the mechanism and host cell proteins
important for this effect. Our data indicate that the P2
motif in NS5A is required for perturbation of EGFR traf-
ficking. Ectopic expression of a ligand for the NS5A P2
motif CMS can recover normal EGFR trafficking. Finally,
we show that NS5A results in a rapid loss of EGFR ubiqui-
tination following EGF stimulation. A schematic for how
we propose NS5A might perturb EGFR trafficking is pre-
sented in Fig. 6.
As for other receptor tyrosine kinases (RTKs), the function
of EGFR is controlled by intracellular trafficking. The acti-
vation of RTKs by growth factors increases turnover and
leads to downregulation of the RTK. Although the control
of EGFR trafficking per se is neither pro- nor antiviral,
EGFR has been assigned several roles in cellular pathways
known to be manipulated during HCV infection. These
include its role as a cofactor during HCV entry, mediated
by CD81–claudin-1 co-receptor association (Diao et al.,
2012; Lupberger et al., 2011) and the role of EGFR
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Fig. 4. CMS can partially rescue EGFR degradation in WT
NS5A-containing cells. Control Huh7 cells, or cell harbouring WT
or PA2 SGR-neo-JFH-1, were transfected with plasmids expres-
sing (a) CMS–PP or (b) Amph2–HA or Grb2–YFP and at 36 h
post-transfection the cells were serum starved overnight prior to
stimulation with 50 ng EGF ml21 for 30 min. Lysates were Wes-
tern blotted (WB) for endogenous EGFR, CMS–PP (using the
streptavidin–HRP antibody), NS5A, GAPDH, Amph2-Myc (using
the Myc epitope antibody) or Grb2–YFP (using the GFP anti-
body) as indicated. Densitometry analysis of EGFR levels is dis-
played as a normalized percentage of GAPDH loading control
underneath the Western blots.
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Fig. 5. NS5A mediates a loss of EGFR ubiquitination and degradation. (a) Control Huh7 cells, or cells harbouring WT or
PA2 SGR-neo-JFH-1, were transiently transfected with plasmids expressing EGFR–GFP and ubiquitin–HA (Ubi–HA).
At 36 h post-transfection the cells were serum starved overnight prior to stimulation with 50 ng EGF ml21 for 0, 15, 30 or
60 min. Lysates were immunoprecipitated (IP) using GFP-Trap beads, and eluted fractions were separated on SDS-PAGE
and probed with antibodies to HA (to detect Ubi–HA) or GFP (to detect EGFR–GFP). Mock, untransfected Huh7 cells (Lane
1). (b) Control Huh7 cells, or cells harbouring WT or PA2 SGR-neo-JFH-1, were transfected with plasmids expressing
EGFR–GFP and Cbl–HA as indicated. At 36 h post-transfection the cells were processed as in (a), prior to Western blotting
(WB) for HA or GFP. (c) Control Huh7 cells, or cells harbouring WT or PA2 SGR-neo-JFH-1, were transiently transfected
with plasmids expressing Grb2–YFP and c-Cbl–HA as indicated. At 36 h post-transfection the cells were processed as in
(a), prior to Western blotting (WB) for HA, YFP (using the GFP antibody) or NS5A. (d) Control Huh7 cells, or cells harbour-
ing WT or PA2 SGR-neo-JFH-1, were transfected with plasmids expressing CMS–PP and c-Cbl–HA as indicated. At 36 h
post-transfection the cells were processed as in (a), prior to precipitation of lysates using streptavidin beads. The eluted frac-
tions were separated on SDS-PAGE and probed with antibodies to HA or NS5A, or with streptavidin–HRP (Strep–HRP; to
detect CMS–PP).
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signalling in the impairment of the antiviral activity of
IFN-a in hepatocytes (Lupberger et al., 2013). Controlling
EGFR degradation may therefore represent a significant
factor in the ability of HCV to avoid host cell immune
responses and aid viral spread. In this regard, it is interest-
ing to note that PA2 mutant HCV viruses, which fail to
inhibit EGF-stimulated EGFR degradation, did not estab-
lish a persistent infection in chimpanzees (Nanda et al.,
2006). In cultured Huh7 cells, introduction of the PA2
mutation did not impair virus replication or assembly/
release (Hughes et al., 2009b). This may indicate a key
role of the NS5A P2 motif in the establishment or mainten-
ance of HCV infection in vivo. The contribution of EGFR
trafficking and signalling during in vivo HCV infection
therefore warrants further investigation.
CMS belongs to the family of ubiquitously expressed adaptor
molecules that can associate with accessory endocytic pro-
teins as well as other adaptor proteins involved in RTK signal-
ling. Whilst NS5A blocks ligand-induced EGFR degradation
through its interaction with this adaptor (Fig. 5a), this did
not correlate with changes in the interaction of EGFR with
its key downstream signalling proteins (c-Cbl, Grb2 and
CMS) (Fig. 5b–d). How the interaction of NS5A with CMS
modulates the ubiquitination of EGFR remains to be eluci-
dated. The loss of EGFR ubiquitination seen in Fig. 5(a) is
consistent with the active recruitment of a deubiquitinating
factor. It is conceivable that this might be accompanied by
inhibition of c-Cbl and/or a block to the recruitment of
other components of the ubiquitin machinery. Experiments
are under way to investigate these hypotheses.
The ability of NS5A to enhance EGFR deubiquitination
reaffirms the role of this post-translational modification
during EGFR endocytosis. Previous observations reported
that when EGFR ubiquitination is inhibited, the receptor
is internalized, but not degraded – an effect mirrored
during HCV infection (Eden et al., 2012). A further ques-
tion that remains is the cellular consequence of manipulat-
ing EGFR ubiquitination during HCV infection. Numerous
lines of epidemiological evidence have indicated that per-
sistent HCV infection is a major risk for the development
of hepatocellular carcinoma (HCC). Clinical studies using
transgenic mouse models, in which the core or NS5A pro-
teins display oncogenic potential, indicate that HCV pro-
teins are directly involved in HCC development (Koike,
2014). Overexpression of EGFR has been reported in
human HCC, and is associated with the late stages of
Fig. 6. Proposed schematic of EGFR trafficking in the presence of NS5A. Upon EGF stimulation, EGFR enters clathrin-
coated vesicles (CCV). Following internalization, EGFR initially traffics through early endosomes, where NS5A was also
shown to partially localize (Mankouri et al., 2008). Activation of the receptor results in EGFR ubiquitination (Ubi) and targeting
for degradation through late endosomal compartments to lysosomes, as a means to terminate EGFR signalling. In the pre-
sence of NS5A, EGFR ubiquitination is blocked and its subsequent trafficking to late endosomal or lysosomal compartments
is delayed by a CMS-dependent mechanism.
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disease, increased cell proliferation and the degree of
tumour differentiation (Berasain et al., 2009; Peschard &
Park, 2003). EGFR progression through the endocytic
pathway is critical for the maintenance of tightly regulated
kinase signalling. Indeed, somatically acquired mutations
in EGFR, which evade ubiquitin-mediated sorting to degra-
dation, are widespread in cancer. By manipulating EGFR
ubiquitination, NS5A may therefore contribute to HCV-
mediated HCC development, which adds to the growing
evidence linking HCV proteins to HCC formation.
In conclusion, we have provided evidence that NS5A
manipulates the ubiquitin system to perturb EGFR traffick-
ing and degradation. The future identification of key mol-
ecules in the ubiquitin and proteasome systems that are
implicated in these NS5A-mediated processes will provide
new insights and an improved understanding of the role
of EGFR in HCV pathogenesis – knowledge that is essential
for the design of novel anti-HCV therapeutics.
METHODS
Cell culture.Huh7 cells were cultured in Dulbecco’s modified Eagle’s
medium supplemented with 10% (v/v) FBS, 100 U penicillin ml21,
100 mg streptomycin ml21, 2 mM L-glutamine and non-essential
amino acids (Gibco) at 37 uC and 5% CO2 in a humidified incubator.
SGR-neo-JFH-1 (Kato et al., 2003) used for this study was derived
from the genotype 2a JFH-1 isolate and was obtained from Takaji
Wakita (National Institute of Infectious Diseases, Japan). A PA2
mutant of SGR-neo-JFH-1 was generated by QuikChange mutagen-
esis targeting the LCSII PxxPxR motif of NS5A. SGR-DPSTCD-neo-
JFH-1 WT and PA2, used in the SH3 domain phage screen, were
created by inserting a DPSTCD (McCormick et al., 2006) tag into the
C terminus of NS5A using an internal Bcl I site. Cells stably har-
bouring SGRs were maintained in the presence of 250 mg G418 ml21
(Melford). A growth curve was produced by seeding 1|105 Huh7,
WT and PA2 SGR-containing cells. Cells were trypsinized at 24, 48
and 72 h post-seeding and counted using a haemocytometer. The
experiment was carried out twice in duplicate.
Antibodies and Western blotting. The polyclonal sheep anti-NS5A
serum has been described previously (Macdonald et al., 2003). Other
antibodies were purchased from the following sources: HA antibody
from Sigma; glyceraldehyde 3-phosphate dehydrogenase (GAPDH)
and GST from Abcam, CMS #2135 (for Western blots) and #5478 (for
immunofluorescence) from Cell Signalling, and GFP and EGFR from
Santa Cruz Biotechnology. Myc-tag antibody was generated in house,
streptavidin-conjugated HRP was obtained from Thermo Scientific,
Texas red-conjugated EGF (EGF–TR) was purchased from Life
Technologies, and mouse anti-CD63 was obtained from Abcam. For
Western blotting, cells were lysed in Glasgow lysis buffer (GLB) as
described previously (Ross-Thriepland & Harris, 2014). Membranes
were probed with appropriate primary antibodies followed by either
HRP-conjugated secondary antibodies (Sigma) or fluorescent sec-
ondary antibodies (LI-COR) and were visualized using an in-house
enhanced chemiluminescence reagent or by using a LI-COR Odyssey
Sa fluorescent imaging system, respectively. Densitometry analysis
was performed on Western blots using ImageJ software.
Plasmid constructs. Full-length CMS was amplified by PCR with
primers containing HindIII restriction sites. The fragment was directly
ligated into a derivative of pcDNA3.1(+) that contained a PinPoint
(PP) biotinylation tag inserted via BamHI and Not I sites. An Amph2-
Myc plasmid was constructed by standard techniques. The NS5A
expression plasmid pSG5-NS5A has been described previously
(Macdonaldet al., 2003). EGFR–GFP was purchased from Addgene.
The ubiquitin-coding sequence was amplified with an N-terminal HA-
tag using KOD polymerase and cloned into the mammalian expression
vector pCMV5 using the BamHI site. Plasmids expressing individual
SH3 domains of CMS as GST fusions were obtained from Kathrin
Kirsch (Boston University, USA), c-Cbl–HA was obtained from Sree-
nivasan Ponnambalam (University of Leeds, UK) and Grb2–YFP was
obtained from Alexander Sorkin (University of Pittsburgh, USA).
Transfection of plasmid DNA and immunoprecipitation. Huh7,
WT SGR-neo-JFH-1- or PA2 SGR-neo-JFH-1-harbouring cells
(1|106) were plated in 90 mm dishes and transfected with 5 mg DNA
of the expression plasmids (Grb2–YFP and Cbl–HA, EGFR–GFP and
Cbl–HA, and EGFR–GFP and ubiquitin–HA; CMS–PP and Cbl–HA)
using polyethyleneimine (Sigma-Aldrich). At 36 h post-transfection,
cells were serum starved overnight and stimulated with 50 ng EGF
ml21 for 30 min. Cells were lysed in GLB (as described above) and
lysates quantified using the bicinchoninic acid protein assay (Thermo
Scientific). Lysate (400 mg) was incubated with either GFP-Trap beads
(Chromotek) or streptavidin-magnetic beads (Life Technologies)
overnight. Beads were washed three times in GLB, eluted by boiling
with 10 ml 1| SDS loading buffer and analysed on SDS-PAGE fol-
lowed by Western blotting. All experiments were repeated a minimum
of three times; Western blots displayed are representative.
Purification of GST–CMS SH3 and GST-pulldown assays. In-
dividual SH3 domains of CMS were expressed as GST fusions and pur-
ified. Briefly, pGEX-4T-1-SH3 expression plasmids were grown in
Escherichia coli BL21(DE3) pLysS at 37 uC until OD600 0.6. The bacteria
were induced with 1 mM IPTG at 37 uC for 3 h and then pelleted by
centrifugation. Bacteria harvested from 400 ml expression cultures were
resuspended in 10 ml PBS, 1% (v/v) Triton X-100 and protease inhibitors
(aprotinin, 2 mg ml21; leupeptin, 1 mg ml21; pepstatin A 1 mg ml21;
Pefabloc, 0.4 mM) (Sigma). The bacteria were lysed by sonication and
clarified by centrifugation. The clarified lysate was added to freshly pre-
pared GA beads (Sigma) and allowed to bind. The beads were washed
twice in PBS plus 1% (v/v) Triton X-100 at 4 uC and then twice in 50 mM
Tris/HCl, pH 8.0. For GST-pulldown experiments, 10 ml GA beads slurry
containing either GST or the GST–CMS SH3 fusions was incubated with
400 mg cell lysate of either WT or PA2 SGR-neo-JFH-1 overnight. Beads
were washed three times with GLB, eluted by boiling with 10 ml 1| SDS
loading buffer and NS5A detected by Western blotting.
Immunofluorescence. Cells were seeded onto coverslips and serum
starved overnight prior to stimulation with 50 ng EGF ml21 for
30 min. Methanol was used for fixation and methanol/acetone (1: 1)
was used for permeabilization. Cells were labelled with sheep poly-
clonal anti-NS5A antibodies, mouse anti-EGFR, mouse anti-CD63,
EGF–TR or rabbit anti-CMS (described above). Alexa Fluor 633- and
488-conjugated donkey anti-sheep, Alexa Fluor 488- and 633-
conjugated goat anti-mouse, and Alexa Fluor 594-conjugated goat
anti-rabbit fluorescent secondary antibodies (Life Technologies) were
used. Overnight serum-starved cells were stimulated with 100 ng
EGF–TR ml21 for 20 min. Cells were then fixed and permeabilized as
described above. Cells were washed with PBS and mounted onto
microscope slides using Citifluor (Agar Scientific). Labelled cells were
viewed on a Zeiss 510-META laser scanning confocal microscope
under an oil immersion |63 objective lens.
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